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ABSTRACT 
 Atrial fibrillation (AF) and chronic kidney disease (CKD) are highly prevalent, particularly 
with increasing of age and associated comorbidities, such as hypertension, diabetes, heart 
failure, and vascular disease. The relationship between AF and CKD seems to be bidirectional. 
CKD predisposes to AF while onset of AF seems to lead to progression of CKD. Stroke 
prevention is the cornerstone of AF management, and AF patients with CKD are at higher risk of 
stroke, mortality, cardiac events, and bleeding. Stroke prevention requires use of oral 
anticoagulants, which are either vitamin K antagonists (e.g. warfarin), or the non-vitamin K 
antagonist oral anticoagulants (NOAC). While NOAC have been shown to be effective in mild-
to-moderate renal dysfunction, there are a paucity of data regarding NOAC in severe and end-
stage renal dysfunction. The followingwill discuss the evidence for NOAC in CKD, and 
summarize the current knowledge regarding the efficacy and safety of NOAC to prevent AF-
related stroke and systemic embolism in severe and end-stage renal disease. 
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Introduction 
Both atrial fibrillation (AF) and 
chronic kidney disease (CKD) are highly 
prevalent, particularly with increasing of age 
and associated comorbidities, such as 
hypertension, diabetes, heart failure, and 
vascular disease. The relationship between 
AF and CKD seems to be directional. CKD 
predisposes to AF, meanwhile onset of AF 
seems to lead to progression of CKD. 
Although it is quite a paradox, CKD itself is 
a risk factor of bleeding. Importantly, the 
concurrence of AF and CKD leads to an 
increased risk of thromboembolic 
complication, including stroke, systemic 
thromboembolism, and myocardial 
infarction.1,2 
 Stroke prevention is the cornerstone 
of AF management and it requires the use 
of oral anticoagulant (OAC), which are 
either vitamin K antagonists (VKA) (e.g. 
warfarin) or non-vitamin K antagonist oral 
anticoagulants (NOAC). 
 While NOAC has been shown to be 
effective in mild-to-moderate renal 
dysfunction with AF, there are a paucity of 
data regarding the use of NOAC in severe 
and end-stage renal dysfunction (ESRD). 
The following will discuss the evidence for 
NOAC in CKD and summarize the current 
knowledge about the efficacy and safety of 
NOAC to prevent AF-related stroke and 
systemic embolism in severe and end-stage 
renal disease.3 
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Discussion 
 Chronic kidney disease is classified 
into stage 1 to 5 based on glomerular 
filtration rate (GFR), or albuminaria that 
persists for > 3 months. GFR can be 
estimated by using the Modification of Diet 
in Renal Disease (MDRD) or Chronic 
Kidney Disease-Epidemiology Collaboration 
group (CKD-EPI) equation4 (Table 1). 
Severe renal dysfunction implies GFR of 
less than 30 mL/min/1.73 m2.5 There is 
variability in the definition of ESRD in 
clinical trials, but the recommended criteria 
for diagnosing ESRD is symptomatic uremia 
that requires chronic renal replacement 
therapy (>30 days). Renal replacement 
therapy can be given through extracorporeal 
modality (hemodialysis) or paracorporeal 
modality (peritoneal dialysis).  
The prevalence of AF in ESRD 
ranges from 7% to 27% in different studies, 
meaning it is 10 to 20 times higher than in 
general population.6  For instance, in a 
prospective study of the Chronic Renal 
Insufficiency Cohort (CRIC) involving 3267 
patients with mild-moderate CKD (mean of 
GFR 43,6 ± 13,4 mL/minute/1.73m2), there 
were 18% of patients indicating that the 
process underlying the onset of AF could 
occur in the early stage of CKD.7
 
 
Table 1. CKD stage and GFR prediction equations4,5 
 
Chronic kidney disease stages 
Stage Descriptor GFR 
1 Kidney damage with normal GFR > 90 
2 Mild renal dysfunction 60-89 
3 Moderate dysfunction 30-59 
4 Severe dysfunction 15-29 
5 Kidney failure < 15 or dialysis-dependent 
GFR prediction equations 
MDRD GFR 
186 × [Cr × 0.0011312] -1.154 
× [age (y)] -0.203 
× [0.742 if female] × [1.212 if black] 
CKD-EPI 
GFR 
Female with Cr < 62 μmol/L; use GFR = 144 × (Cr/61.6)-0.329 × (0.993)Age 
Female with Cr > 62 μmol/L; use GFR = 144 × (Cr/61.6)-1.209 × (0.993)Age 
 
Male with Cr < 80 μmol/L; use GFR = 141 × (Cr/79.2)-0.411 × (0.993)Age 
Male with Cr > 80 μmol/L; use GFR = 141 x (Cr/79.2)-1.209 × (0.993)Age 
 CKD-EPI: Chronic Kidney Disease-Epidemiology Collaboration; Cr: creatinine;  
            GFR: glomerular filtration rate;  MDRD: Modification of  Diet in Renal Disease. 
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 Atrial fibrillation can contribute to 
progression of CKD as well. Subgroup 
analysis from CRIC study found a higher 
rate of development of ESRD in CKD 
patients with AF (11.8/100 person-year) 
compared to in CKD patients who were not 
accompanied by AF (3.4/100 person-year) 
during mean follow-up 5.9 years.8 
Therefore, the relationship between AF and 
renal dysfunction is bidirectional. Mortality 
associated with incidence of AF has been 
shown to be higher in patients with CKD 
(survival rate at 12 months 63.4%-68.3%) 
than in patients without CKD (survival rate 
at 12 months 79.3%).9 
 
Stroke, bleeding risk, and thrombo- 
prophylaxis in AF 
 Atrial fibrillation escalates the risk of 
stroke, but this risk is not homogenous and 
it depends on various risk factors. More 
general and validated stroke risk factors 
have been used to formulate stroke risk 
stratification score, such as 
CHA2Ds2VASc.10 The risk of stroke is not 
static and regular reassessment is needed, 
given the increasing age and risk factor of 
stroke events over time.11 
 Recognizing that CKD increases the 
risk of stroke, several studies have 
suggested adding CKD and renal 
replacement (for example proteinuria) to risk 
scores, such as ATRIA score or 
R2CHADS2 score.12,13 However, other 
studies have not shown any added value for 
stroke event prediction by considering CKD. 
14, 15, 16 This may not be surprising because 
CKD is strongly associated with individual 
components from CHA2DS2VASc score.  
 Chronic kidney disease predisposes 
to an increased risk of bleeding as well. 
Although many bleeding risk factors have 
been described including various 
biomarkers, risk factors of bleeding and 
stroke are often found similar, therefore the 
higher the risk of stroke, the higher the 
bleeding. In this case, HASBLED score, 
which combines validated bleeding risk 
factor, has been proposed to assess the risk 
of bleeding.17 The use of appropriate 
HASBLED score is to draw attention to 
modifiable bleeding risk factors, and to mark 
patients with high bleeding risk to be more 
frequently reviewed and followed-up.18 An 
approach that only focuses on modifiable 
risk factors for bleeding is an inferior study 
compared to HASBLED for predicting the 
risk of bleeding. 11, 19, 20 
Thromboprophylaxis in AF required 
oral anticoagulants, VKA which has to be 
managed properly (e.g. warfarin) or NOAC 
(e.g. apixaban, rivaroxaban, edoxaban, and 
dabigatran).3 However, warfarin and NOAC 
work on difference coagulation pathways in 
their mechanisms of action. Warfarin inhibits 
vitamin K II, VII, IX, and X-dependent 
clotting factors to interfere international 
normalized ration (INR), where low INR 
increases the risk of clotting and high INR 
increases the risk of bleeding. On the other 
hand, NOAC targets individual clotting 
proteins (apixaban, rivaroxaban, and 
edoxaban directly inhibit factor X and 
dabigatran directly inhibits thrombin).12 
(Figure 1). 
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Figure 1. Mechanism of action of NOAC12 
  
 A prospective study of 565 patients 
who were using warfarin showed that 
individuals with severe renal dysfunction 
(GFR < 30 mL/minute/ 1.73 kg/m2) required 
lower warfarin doses and fewer time in 
therapeutic range (TTR). In addition, the 
rate of major bleeding events was greater 
(30.5 per 100 patients/year) than in patients 
with mild renal dysfunction (6.2 per 100 
patients/year). The use of warfarin is also 
complicated by several drug and dietary 
interactions, in addition to reduction of 
vitamin K-dependent matrix G1a protein, 
which results in increased vascular 
calcification.22 Warfarin-related nephropathy 
resulting from glomerular bleeding and 
tubular obstruction by red blood cell casts is 
more frequently seen in patients with CKD. 
23 
 Non-vitamin K oral anticoagulants 
have changed the landscape for stroke 
prevention in AF. Although regional 
differences are evident,24 in contrast to 
warfarin, NOAC has fewer drug and dietary 
interactions, has rapid onset of action, and 
does not require regular laboratory 
monitoring. Short half-life gives a very 
necessary meaning to patients’ adherence. 
 When glomerular filtration is 
disrupted, the clearance of NOAC 
decreases as well, therefore the plasma 
half-life becomes extended. This can result 
in an increase in total medication exposure 
or area under curve (AUC), which increases 
the risk of bleeding complications.25 
Dabigatran has significant renal clearance 
(80% are excreted through kidney) with 
lower renal excretion can be seen 
consecutively in edoxaban (50%), 
rivaroxaban (33%), and apixaban (27%).26 
There is limited data for the use of NOAC in 
severe renal dysfunction and ESRD 
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(Cockcroft-Gault clearance creatinine 
[CrCI]< 25-30 mL/minute) because these 
patients were excluded from phase III in a 
randomized study.27 
 
Important clinical research data that 
supports the use of NOAC in AF and 
CKD 
Phase III trial, which supports the 
use of NOAC to prevent thromboembolism 
in AF, was carried out with NOAC specific 
dose and patient exclusion criteria. Patients 
with < 30 mL/minute CrCl (dabigatran, 
rivaroxaban, and edoxaban) or CrCl< 25 
mL/minute (apixaban) were excluded from 
this important clinical trial.28, 29, 30, 31 
The recommendations of the 
European Society of Cardiology for 
moderate CKD (GFR 30-59 mL/minute) are 
based on secondary analysis of phase III 
NOAC trials.32  On the other hand, Food and 
Drug Administration (FDA) in the United 
States of America has agreed to reduce 
doses of dabigatran 75 mg twice daily, 
apixaban 5 mg twice daily (apixaban 2.5 mg 
twice daily if ≥ 80 years ≤ 60 kg), and 
rivaroxaban 15 mg twice daily in patients 
with CrCl 15 to 29 mL/minute, mainly based 
on pharmacological modelling data for CrCl 
15 to 29 mL/minute (Table 3). 33, 34, 35, 36, 37 
In a meta-analysis of 13,888 AF 
patients with moderate CKD, some NOACs 
were compared through surface under the 
cumulative ranking (SUCRA) curve 
assessment. Dabigatran 150 mg twice daily 
was the most efficacious (SUCRA 0.96) 
followed by apixaban, rivaroxaban, and 
edoxaban consecutively (SUCRA 0.67, 
0.53, 0.51). Apixaban (SUCRA 0.84) and 
edoxaban (SUCRA 0.61) have the best 
safety profiles.38 
 
Clinical consideration 
 In clinical practice, we need to try to 
use CrCl in estimating kidney function to 
decide appropriate anticoagulants strategy, 
as reflected in the closest clinical trial. 
Indeed, previous studies have shown 
differences in the estimation of GFR when 
using Cockcroft-Gault, CKD-EPI, and 
MDRD formulas. Patients who are 
prescribed with NOAC should also be 
monitored for kidney function to ensure that 
they are consistently prescribed for the right 
dose. For example, a study in primary care 
showed that annual kidney function 
monitoring identified patients who 
experienced over- or under-coagulation.39 
Furthermore, adherence to kidney function 
monitoring has been proven to increase the 
likelihood of adequate NOAC doses at 1-
year follow-up.40 
We must also consider adjusting 
NOAC dose in acute-on-chronic kidney 
injury. In an observational study of 162 
patients with concurrent AF and heart 
failure, fluctuations measured in kidney 
function needed dose adjustments (44%, 
35%, 29% of patients using dabigatran, 
rivaroxaban, and apixaban).41 Figure 2 
describes the flow of management of atrial 
fibrillation.
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 Figure 2. Atrial fibrillation management algorithm. When warfarin is used, it has to achieve time in 
therapeutic range ≥ 70%. 
  
Conclusion 
 The decision to use anticoagulants 
in patients with concurrent AF and CKD 
depends on CKD stages, keeping in mind 
the appropriate balance between prevention 
of thromboembolism and excessive 
bleeding, particularly in ESRD. In moderate 
CKD, available data showed that NOAC is 
atleast noninferior to warfarin in preventing 
stroke and systemic embolism with similar 
safety profiles. In severe kidney failure 
(GFR 15-20 mL), the use of NOAC is not 
routinely recommended because several 
important studies do not include this group 
of patients. EHRA practical guideline 
generally prefers the use of warfarin in this 
group of patients. Although FDA has 
approved reduction of NOAC dose in severe 
kidney damage, it is based on 
pharmacokinetic studies rather than 
prospective clinical trials. 
 The algorithm for managing atrial 
fibrillation, when warfarin is used, it must 
reach time in therapeutic range ≥ 70%. 
 An individual approach is required to 
evaluate the risks compared to the benefits 
of anticoagulants in patients with AF and 
ESRD, because there is certain evidence of 
pros and cons of their use. There are no 
RCT which explores the use of NOAC in 
ESRD. The result of the biggest head-to-
head study available in patients using 
dabigatran, rivaroxaban, or warfarin raises 
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concerns about the used of NOAC 
(particularly dabigatran) in hemodialyzed 
patients due to increased bleeding risk. 
Therefore, at present, warfarin has more 
evidences supporting its use in AF patients 
with ESRD for prevention of stroke and 
systemic thromboembolism. 
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